Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Translating anti-CD19 CAR T-Cell therapy into clinical practice for relapsed/refractory diffuse large B-Cell lymphoma.

Chow VA, Shadman M, Gopal AK.

Blood. 2018 Jun 18. pii: blood-2018-04-839217. doi: 10.1182/blood-2018-04-839217. [Epub ahead of print]

PMID:
29914976
2.

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G.

J Clin Oncol. 2018 May 31:JCO2017768853. doi: 10.1200/JCO.2017.76.8853. [Epub ahead of print]

PMID:
29851546
3.

Have we found the right patient population for transplantation in follicular lymphoma?

Lynch RC, Gopal AK.

Cancer. 2018 Jun 15;124(12):2484-2487. doi: 10.1002/cncr.31376. Epub 2018 Apr 12. No abstract available.

PMID:
29645081
4.

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, Thall AD, Gopal AK.

Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16.

PMID:
29549159
5.

Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.

Cowan AJ, Stevenson PA, Libby EN, Becker PS, Coffey DG, Green DJ, Hyun TS, Fromm JR, Gopal AK, Holmberg LA.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1386-1391. doi: 10.1016/j.bbmt.2018.02.017. Epub 2018 Mar 1.

PMID:
29481870
6.

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW.

Lancet Haematol. 2018 Mar;5(3):e102-e108. doi: 10.1016/S2352-3026(18)30001-2. Epub 2018 Jan 26.

PMID:
29396094
7.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.

J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.

PMID:
29356608
8.

Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation.

Li A, Davis C, Wu Q, Li S, Kesten MF, Holmberg LA, Gopal AK, Garcia DA.

Blood Adv. 2017 Apr 27;1(12):707-714. doi: 10.1182/bloodadvances.2017006130. eCollection 2017 May 9.

9.

Long-term results of a sirolimus-eluting stent with biodegradable polymer (RAPSTROM™) in de novo coronary stenoses.

Figini F, Manjunath CN, Srinivas BC, Sadananda KS, Sreedharan M, Fischer L, Pillai R, Varghese K, Gopal AK, Nagesh CM, Sheiban I.

Cardiovasc Revasc Med. 2018 Jun;19(4):429-432. doi: 10.1016/j.carrev.2017.10.003. Epub 2017 Oct 7.

PMID:
29174500
10.

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, Wilbur DS, Fisher DR, Nartea M, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, Orcutt KD, Wittrup KD, Press OW.

Blood. 2018 Feb 8;131(6):611-620. doi: 10.1182/blood-2017-09-807610. Epub 2017 Nov 20.

PMID:
29158362
11.

Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.

Tseng YD, Stevenson PA, Cassaday RD, Cowan A, Till BG, Shadman M, Graf SA, Ermoian R, Smith SD, Holmberg LA, Press OW, Gopal AK.

Biol Blood Marrow Transplant. 2018 Feb;24(2):282-287. doi: 10.1016/j.bbmt.2017.10.029. Epub 2017 Oct 20.

PMID:
29061536
12.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1826-1838. doi: 10.1016/j.bbmt.2017.07.027. Epub 2017 Aug 7.

PMID:
28797780
13.

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, Wilbur DS, Hamlin DK, Fisher DR, Hylarides MD, Gooley TA, Waltman A, Till BG, Press OW.

Cancer Res. 2017 Jul 15;77(14):3885-3893. doi: 10.1158/0008-5472.CAN-17-0082. Epub 2017 May 31.

14.

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.

Gopal AK, Fanale MA, Moskowitz CH, Shustov AR, Mitra S, Ye W, Younes A, Moskowitz AJ.

Ann Oncol. 2017 May 1;28(5):1057-1063. doi: 10.1093/annonc/mdx028.

PMID:
28327905
15.

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW.

Blood. 2017 Jun 1;129(22):3037-3039. doi: 10.1182/blood-2016-12-757740. Epub 2017 Mar 21. No abstract available.

16.

Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review.

Potts DA, Fromm JR, Gopal AK, Cassaday RD.

Case Rep Hematol. 2017;2017:2676254. doi: 10.1155/2017/2676254. Epub 2017 Feb 21.

17.

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

Yan F, Gopal AK, Graf SA.

Pharmaceuticals (Basel). 2017 Mar 10;10(1). pii: E28. doi: 10.3390/ph10010028. Review.

18.

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.

Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):225-230. doi: 10.1016/j.clml.2016.12.004. Epub 2017 Jan 10.

PMID:
28169156
19.

Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Mostaghel EA, Martin PS, Mongovin S, Frayo S, Zhang A, Edlefsen KL, Press OW, Gopal AK.

Exp Hematol. 2017 May;49:34-38.e2. doi: 10.1016/j.exphem.2017.01.001. Epub 2017 Jan 21.

20.

Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.

Cowan AJ, Stevenson PA, Gooley TA, Frayo SL, Oliveira GR, Smith SD, Green DJ, Roden JE, Pagel JM, Wood BL, Press OW, Gopal AK.

Br J Haematol. 2017 Feb;176(4):583-590. doi: 10.1111/bjh.14451. Epub 2017 Jan 5.

21.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR.

J Natl Cancer Inst. 2016 Dec 31;109(1). pii: djw263. doi: 10.1093/jnci/djw263. Print 2017 Jan. Review.

PMID:
28040733
22.

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK.

Haematologica. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15. No abstract available.

23.

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.

Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN.

Amyloid. 2016 Dec;23(4):254-259. Epub 2016 Nov 23.

24.

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, O'Steen S, Orcutt KD, Wilbur DS, Wittrup KD, Press OW.

Cancer Res. 2016 Nov 15;76(22):6669-6679. doi: 10.1158/0008-5472.CAN-16-0571. Epub 2016 Sep 2.

25.

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.

Gauthier J, Holmberg L, Wu D, Bensinger W, Gopal AK, Press O, Maloney D, Green DJ, Till BG, Byelykh D, Shustov A.

Bone Marrow Transplant. 2016 Dec;51(12):1617-1619. doi: 10.1038/bmt.2016.227. Epub 2016 Oct 24. No abstract available.

PMID:
27775693
26.

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A.

Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.

27.

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, McCune JS, Bensinger WI, Maloney DG, Press OW, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1582-1587. doi: 10.1016/j.bbmt.2016.06.007. Epub 2016 Jun 14.

28.

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Green DJ, Bensinger WI, Holmberg LA, Gooley T, Till BG, Budde LE, Pagel JM, Frayo SL, Roden JE, Hedin L, Press OW, Gopal AK.

Bone Marrow Transplant. 2016 Oct;51(10):1330-1336. doi: 10.1038/bmt.2016.123. Epub 2016 May 23.

29.

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ, Maloney DG, Riddell SR, Till BG.

Cancer Immunol Res. 2016 Jun;4(6):509-19. doi: 10.1158/2326-6066.CIR-15-0276. Epub 2016 Apr 21.

30.

Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.

Gopal AK, Pro B, Connors JM, Younes A, Engert A, Shustov AR, Chi X, Larsen EK, Kennedy DA, Sievers EL.

Clin Trials. 2016 Oct;13(5):545-54. doi: 10.1177/1740774516645338. Epub 2016 May 5.

31.

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.

Zhao B, Chen R, O'Connor OA, Gopal AK, Ramchandren R, Goy A, Matous JV, Fasanmade AA, Manley TJ, Han TH.

Br J Clin Pharmacol. 2016 Sep;82(3):696-705. doi: 10.1111/bcp.12988. Epub 2016 May 29.

32.

Idelalisib for the treatment of non-Hodgkin lymphoma.

Graf SA, Gopal AK.

Expert Opin Pharmacother. 2016;17(2):265-74. doi: 10.1517/14656566.2016.1135130. Epub 2016 Jan 28. Review.

33.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS, Hylarides MD, Frost SH, Mawad R, O'Donnell P, Sandmaier BM, Fuchs EJ, Luznik L, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2016 Jan 21;127(3):352-9. doi: 10.1182/blood-2014-12-617019. Epub 2015 Nov 17.

34.

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.

Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK.

Br J Haematol. 2015 Dec;171(5):788-97. doi: 10.1111/bjh.13773. Epub 2015 Oct 12.

35.

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK, Green DJ, Press OW, Lill M, Ifthikharuddin JJ, Vescio R, Holmberg LA, Phillips GL.

Bone Marrow Transplant. 2016 Jan;51(1):67-71. doi: 10.1038/bmt.2015.211. Epub 2015 Sep 14.

36.

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN 3rd, Bensinger WI, Shadman M, Maloney DG, Press OW, Gopal AK.

Biol Blood Marrow Transplant. 2016 Feb;22(2):380-385. doi: 10.1016/j.bbmt.2015.08.035. Epub 2015 Sep 5.

37.

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN 3rd, Bensinger WI, Pagel JM, Maloney DG, Zhou Y, Cassaday RD, Gopal AK.

Ann Oncol. 2015 Nov;26(11):2323-8. doi: 10.1093/annonc/mdv364. Epub 2015 Sep 7.

38.

Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.

Cowan AJ, Frayo SL, Press OW, Palanca-Wessels MC, Pagel JM, Green DJ, Gopal AK.

Anticancer Drugs. 2015 Oct;26(9):974-83. doi: 10.1097/CAD.0000000000000274.

39.

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.

Shadman M, Gopal AK, Kammerer B, Becker PS, Maloney DG, Pender B, Shustov AR, Press OW, Pagel JM.

Leuk Lymphoma. 2016;57(3):572-6. doi: 10.3109/10428194.2015.1067701. Epub 2015 Aug 28.

40.

New targeted therapies for indolent B-cell malignancies in older patients.

Krem MM, Gopal AK.

Am Soc Clin Oncol Educ Book. 2015:e365-74. doi: 10.14694/EdBook_AM.2015.35.e365. Review.

41.

A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Cassaday RD, Goy A, Advani S, Chawla P, Nachankar R, Gandhi M, Gopal AK.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):392-7. doi: 10.1016/j.clml.2015.02.021. Epub 2015 Mar 5.

42.

Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.

Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM, Bäck TA, Fisher DR, Press OW.

PLoS One. 2015 Mar 18;10(3):e0120561. doi: 10.1371/journal.pone.0120561. eCollection 2015.

43.

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Graf SA, Gopal AK.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):151-7. doi: 10.1182/asheducation-2014.1.151. Epub 2014 Nov 18. Review.

44.

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Bäck T, Sandmaier BM, Pagel JM, Press OW.

Blood. 2015 Mar 26;125(13):2111-9. doi: 10.1182/blood-2014-11-612770. Epub 2015 Jan 27.

45.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A.

Blood. 2015 Feb 19;125(8):1236-43. doi: 10.1182/blood-2014-08-595801. Epub 2014 Dec 22.

46.

Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

Orozco JJ, Balkin ER, Gooley TA, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Hylarides MD, Shadman M, Green DJ, Gopal AK, Press OW, Pagel JM.

PLoS One. 2014 Dec 2;9(12):e113601. doi: 10.1371/journal.pone.0113601. eCollection 2014.

47.

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

Cassaday RD, Storer BE, Sorror ML, Sandmaier BM, Guthrie KA, Maloney DG, Rajendran JG, Pagel JM, Flowers ME, Green DJ, Rezvani AR, Storb RF, Press OW, Gopal AK.

Biol Blood Marrow Transplant. 2015 Feb;21(2):281-7. doi: 10.1016/j.bbmt.2014.10.024. Epub 2014 Nov 1.

48.

Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.

Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM, Roden JE, Maloney DG, Green DJ, Till BG, Press OW, Smith SD, Gopal AK.

Hematol Oncol. 2015 Dec;33(4):187-91. doi: 10.1002/hon.2166. Epub 2014 Sep 18.

49.

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.

Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK.

Br J Haematol. 2015 Jan;168(1):38-45. doi: 10.1111/bjh.13099. Epub 2014 Aug 22.

PMID:
25146490
50.

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.

Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK.

Leuk Lymphoma. 2015 Apr;56(4):1151-3. doi: 10.3109/10428194.2014.951843. Epub 2014 Oct 7. No abstract available.

PMID:
25110824

Supplemental Content

Loading ...
Support Center